Genitourinary (GU) schistosomiasis is caused by Schistosoma haematobium, a blood fluke endemic to sub-Saharan Africa and the Middle East, acquired through freshwater contact with cercariae released by Bulinus snails. [1-2] Adult worms reside in the pelvic venous plexus, and egg deposition in the bladder and urogenital tract drives granulomatous inflammation, fibrosis, and potentially squamous cell carcinoma of the bladder — classified as a Group 1 carcinogen by the IARC/WHO. [3-4]
The following figure demonstrates the pathological consequences of chronic schistosomiasis, including bladder granuloma, bilateral hydronephrosis on CT, and hepatic fibrosis on ultrasound:
1. History
- Exposure history is paramount: freshwater contact (swimming, bathing, wading, washing) in endemic areas of sub-Saharan Africa, Middle East, or Corsica (recent focus) [1][5]
- Timing of exposure relative to symptom onset: acute symptoms (Katayama fever) 2–12 weeks post-exposure; chronic GU symptoms ≥10–12 weeks [4-5]
- Hematuria — classically terminal (end-stream), may progress to gross/frank hematuria in severe cases [4][6]
- Dysuria, urinary frequency (pollakisuria), suprapubic pain [6]
- Hemospermia in males [7-8]
- Genital symptoms in females: vaginal discharge, contact bleeding, dyspareunia, pelvic pain [8]
- Prior treatment with praziquantel and response
- Immigration/travel history — duration and recency of time in endemic area
- Occupational exposure (farming, fishing, laundry work near freshwater)
2. Alarm Features
- Obstructive uropathy: flank pain, decreased urine output, signs of renal failure (hydroureter/hydronephrosis) [6][8]
- Bladder mass or persistent gross hematuria — raises concern for squamous cell carcinoma of the bladder [3-4]
- Neurological symptoms (lower extremity weakness, urinary retention, saddle anesthesia) — suggests spinal cord involvement/transverse myelitis from ectopic egg deposition [5]
- Fever with rigors in a recently exposed, infection-naïve traveler — Katayama syndrome [9]
- Signs of renal failure: edema, oliguria, nephrotic-range proteinuria [4]
- Infertility, recurrent miscarriage, or ectopic pregnancy in women from endemic areas [2][8]
3. Medications
- Praziquantel (Biltricide) — first-line treatment: 20 mg/kg orally three times in one day, doses separated by 4–6 hours, taken with food [4][10]
- Community-based programs often use a single dose of 40 mg/kg [4][8]
- Cures 60–90% of patients; those still shedding viable eggs should be re-treated [4]
- Active against adult worms only; poor activity against immature schistosomulae — treatment should be delayed ≥6–8 weeks post-exposure to allow worm maturation [5][10]
- Safe in pregnancy after the first trimester and in lactating women [2]
- Common side effects: abdominal pain, headache, dizziness, nausea (self-limited, peak 2–4 hours post-dose) [8]
- Corticosteroids may be used as adjunct for severe Katayama fever or CNS disease with surrounding edema [4]
- Artemisinin derivatives (artesunate, artemether) have activity against immature larvae; combination with praziquantel may improve cure rates, but not yet standard practice and carries risk of promoting artemisinin-resistant malaria [8]
- Contraindicated/caution: Avoid praziquantel in ocular cysticercosis (unrelated but important co-infection consideration); strong CYP450 inducers (rifampin) reduce praziquantel levels significantly [10]
4. Diet
- Take praziquantel with food — improves bioavailability and reduces GI side effects [10]
- No specific dietary triggers for the disease itself
- Ensure adequate hydration, especially in patients with hematuria or renal impairment
- Long-term: address malnutrition and iron deficiency anemia common in chronically infected individuals [8]
5. Review of Systems
- GU: hematuria (gross/micro), dysuria, frequency, urgency, flank pain, hemospermia, vaginal discharge/bleeding
- Constitutional: fever, malaise, weight loss, fatigue (especially acute phase)
- Dermatologic: pruritic papular rash (swimmer's itch) within hours to days of exposure [5][9]
- Respiratory: cough, wheeze (acute Katayama or pulmonary egg migration)
- GI: abdominal pain, diarrhea (may indicate co-infection with S. mansoni)
- Neurologic: lower extremity weakness, bowel/bladder dysfunction (spinal cord involvement)
- Reproductive: infertility, menstrual irregularities, dyspareunia [8]
- Hematologic: fatigue/pallor (anemia)
6. Collateral History and Family History
- Other household members or travel companions with similar freshwater exposure — screen contacts
- In endemic regions, haematuria is so common it may be considered a normal sign of puberty in boys or confused with menses in girls [6][8]
- Family history of bladder cancer in endemic populations
- Immigration history: country of origin, duration of residence, prior mass drug administration participation
- HIV status — GU schistosomiasis increases HIV transmission risk, particularly female genital schistosomiasis [2][8]
7. Risk Factors
- Residence in or travel to endemic areas: sub-Saharan Africa (highest burden), Middle East, parts of Southeast Asia [1-2]
- Freshwater contact in endemic regions — swimming, bathing, agricultural work, fishing [9]
- School-aged children and young adults — highest prevalence and intensity of infection [6][11]
- Male sex — higher occupational exposure; male smokers at particular risk for schistosomiasis-associated bladder cancer [4]
- Poverty, lack of clean water and sanitation [11]
- Immunosuppression (transplant recipients) — worms may persist up to 5 years; cannot reproduce but cause ongoing egg-mediated damage [12]
8. Differential Diagnosis
- Urinary tract infection (bacterial cystitis) — dysuria and hematuria overlap; distinguish by urine culture and travel history
- Bladder cancer (transitional cell carcinoma) — painless hematuria in older patients; schistosomiasis-associated SCC tends to occur at younger ages [4]
- Urolithiasis — renal colic, hematuria; CT KUB differentiates
- Glomerulonephritis — proteinuria, hematuria, RBC casts
- Tuberculosis of the urinary tract — sterile pyuria, calcifications; AFB cultures
- Interstitial cystitis — chronic dysuria/frequency without infection
- Sexually transmitted infections — genital lesions from schistosomiasis may mimic condylomata lata or HPV warts [4]
- IgA nephropathy — recurrent gross hematuria
- Other parasitic infections: filariasis (chyluria), trichomonas
9. Past Medical History
- Prior schistosomiasis diagnosis and treatment (praziquantel response, number of courses)
- History of recurrent UTIs or hematuria
- Known bladder pathology, urolithiasis, or prior urologic surgery
- Chronic kidney disease
- HIV/AIDS status (impacts genital schistosomiasis management and transmission risk) [2][8]
- Prior organ transplantation [12]
- Smoking history (synergistic bladder cancer risk) [4]
10. Physical Exam
- Vital signs: fever (acute Katayama); otherwise often normal in chronic disease
- Abdominal exam: suprapubic tenderness, palpable bladder (obstruction); flank tenderness (hydronephrosis); hepatosplenomegaly (co-infection or ectopic egg deposition) [5]
- Genital exam:
- Females: sandy patches on colposcopy (pathognomonic for female genital schistosomiasis), neovascularization, friable cervical/vaginal mucosa, contact bleeding [8-9]
- Males: epididymal tenderness, scrotal masses (orchitis), prostatic tenderness on DRE [7-8]
- Skin: cercarial dermatitis (pruritic papular rash at exposure sites) in acute phase [5]
- Neurologic exam: lower extremity strength, reflexes, perineal sensation (if CNS involvement suspected)
11. Lab Studies
- Urinalysis: hematuria (micro or gross, classically terminal), proteinuria, leukocyturia — dipstick is a rapid point-of-care screen [13]
- Urine microscopy for ova: definitive diagnosis — look for S. haematobium eggs with characteristic terminal spine; collect midday urine (10 AM–2 PM) after exercise for maximal egg shedding [4][7]
- Serology (ELISA, IHA, or rapid ICT IgG-IgM): high sensitivity (~100% in confirmed cases), but cannot distinguish active from past infection; cross-reactivity with other helminths reduces specificity to ~85% [12][14-15]
- Circulating anodic antigen (CAA): most accurate test for active infection and treatment monitoring [16]
- Real-time PCR (serum, urine, or stool): high sensitivity and specificity; serum PCR sensitivity ~73% overall, ~94% in egg-positive patients; useful for species identification [17]
- CBC: eosinophilia (common in both acute and chronic infection); anemia (chronic disease) [5][9]
- BMP/CMP: creatinine, BUN (assess renal function); electrolytes
- Liver function tests: if co-infection with S. mansoni suspected
The following figure shows the morphology of schistosome eggs — the terminal spine of S. haematobium is the key distinguishing feature:
12. Imaging
- Ultrasound (first-line):
- Bladder wall thickening (>5 mm), mucosal irregularity, pseudopolyps [18-20]
- Echogenic snow sign — scattered echogenic foci floating in bladder lumen (newer criterion) [19]
- Hydroureter, hydronephrosis [20-21]
- Bladder calcifications (less sensitive than CT/plain film) [22]
- CT abdomen/pelvis:
- Fine linear ureteral calcifications (line or parallel lines on plain film; circular pattern on axial CT) — considered pathognomonic of early-stage GU schistosomiasis [7]
- Coarse bladder wall calcification (chronic/late-stage) [7][23]
- Bladder masses (concern for SCC) [7]
- Bilateral hydronephrosis with renal atrophy in advanced disease [4]
- Plain abdominal radiograph: may show bladder/ureteral calcifications ("fetal head" sign of calcified bladder)
- CT urography/IVP: filling defects from pseudopolyps, ureteral strictures [7]
- MRI: useful for CNS involvement (spinal cord granulomas) and female genital schistosomiasis assessment [24]
- Imaging may be unnecessary in uncomplicated early infection with confirmed ova in urine
13. Special Tests
- Cystoscopy: sandy patches (roughened bladder mucosa surrounding egg deposits) are pathognomonic; pseudopolyps, ulceration; biopsy for histology (granulomas with terminal-spined eggs) and to rule out malignancy [4]
- Colposcopy (females): sandy patches — grainy or homogeneous yellow patches, rubbery papules — pathognomonic for female genital schistosomiasis [8-9]
- Urine reagent dipstick: rapid POC screening for microhematuria and proteinuria [13]
- POC-CCA urine test: primarily validated for S. mansoni; limited utility for S. haematobium [16]
- Rectal/bladder biopsy: crush preparation for egg identification when urine microscopy is negative
14. ECG
- Not routinely indicated
- Consider if pulmonary hypertension is suspected (right heart strain pattern: right axis deviation, P pulmonale, RV hypertrophy) — rare complication from chronic egg embolization to pulmonary vasculature
- Echocardiography preferred for pulmonary hypertension assessment
15. Assessment
- Acute GU schistosomiasis: hematuria and dysuria appearing 10–12 weeks post-freshwater exposure in an endemic area, with eosinophilia [4]
- Chronic GU schistosomiasis: persistent/recurrent hematuria, dysuria, proteinuria; imaging showing bladder wall thickening, calcifications, or obstructive uropathy [6-7]
- Severity stratification:
- Mild: microhematuria, no structural changes
- Moderate: gross hematuria, bladder wall thickening, early ureteral changes
- Severe: hydronephrosis, renal impairment, bladder calcification, suspected malignancy [6][8]
- Complications: obstructive uropathy → renal failure; SCC of bladder; female genital schistosomiasis → infertility, increased HIV risk; bacterial superinfection; bladder stones [2][4][8]
- Most lesions, including hydronephrosis, heal well after treatment if reinfection is avoided [6]
16. Treatment Plan
- Praziquantel 20 mg/kg PO × 3 doses in one day (separated by 4–6 hours, with food) [10]
- Alternative field dosing: single dose 40 mg/kg [4][8]
- Do not chew tablets (bitter taste causes vomiting); crush for children <6 years [10]
- Timing: delay treatment ≥6–8 weeks post-exposure to allow worm maturation (praziquantel ineffective against immature schistosomulae) [5][10]
- Re-examine urine 1 month post-treatment for persistent egg shedding; re-treat if positive [4]
- Acute Katayama syndrome: corticosteroids (e.g., prednisone) for severe symptoms, followed by praziquantel once acute inflammation subsides [4]
- Obstructive uropathy: urology consultation for ureteral stenting or nephrostomy if needed
- Suspected bladder malignancy: cystoscopy with biopsy → oncology/urology referral
- Female genital schistosomiasis: praziquantel treatment; note that advanced genital tract damage may not fully resolve [8]
- Male genital involvement (orchitis, prostatitis, hemospermia): generally resolves more readily after treatment [8]
17. Disposition
- Outpatient management appropriate for most cases — uncomplicated hematuria/dysuria with confirmed or suspected GU schistosomiasis
- Admission criteria:
- Acute renal failure or severe obstructive uropathy
- Severe Katayama syndrome (high fevers, respiratory distress)
- CNS involvement (transverse myelitis) — requires IV corticosteroids
- Suspected bladder malignancy requiring urgent workup
- Specialist consultation triggers:
- Infectious disease/tropical medicine: all cases in non-endemic settings [5]
- Urology: obstructive uropathy, bladder mass, persistent hematuria post-treatment
- Gynecology: female genital schistosomiasis, infertility workup
- Oncology: confirmed or suspected SCC of bladder
- Nephrology: renal impairment, nephrotic-range proteinuria
18. Follow-Up / Return Precautions
- Urine re-examination at 4 weeks post-treatment for egg clearance; re-treat if eggs persist [4-5]
- Repeat treatment at 2–4 weeks may be needed in lightly infected patients (less robust immune response) [5]
- Serology remains positive for months to years after cure — not useful for confirming treatment success; CAA or serum PCR are better markers (PCR negativity by ~12 months post-treatment) [15-17]
- Imaging follow-up (ultrasound) at 3–6 months to assess resolution of bladder wall thickening and hydronephrosis [20-21]
- Long-term bladder cancer surveillance in patients with chronic/heavy infection — periodic urinalysis, urine cytology, and cystoscopy as clinically indicated [25]
- Return precautions: worsening hematuria, flank pain, decreased urine output, fever, neurological symptoms (leg weakness, urinary retention), unexplained weight loss
- Counsel on re-exposure avoidance: no freshwater contact in endemic areas; no vaccine or chemoprophylaxis currently available [5]
- Screen household members/travel companions with shared exposure history
References
1. Human Schistosomiasis. — Buonfrate D, Ferrari TCA, Adegnika AA, Russell Stothard J, Gobbi FG. Lancet. 2025.
2. Review of 2022 WHO Guidelines on the Control and Elimination of Schistosomiasis. — Lo NC, Bezerra FSM, Colley DG, et al. The Lancet. Infectious Diseases. 2022.
3. Oxidative Stress and Cancer Risk in Schistosomiasis. — Afrifa J, Ofori EG, Opoku YK, et al. Oxidative Medicine and Cellular Longevity. 2024.
4. Schistosomiasis. — Ross AG, Bartley PB, Sleigh AC, et al. The New England Journal of Medicine. 2002.
5. Schistosomiasis. — Anne Straily and W. Evan Secor CDC Yellow Book. 2025.
6. Human Schistosomiasis. — Gryseels B, Polman K, Clerinx J, Kestens L. Lancet. 2006.
7. Genitourinary Schistosomiasis: Life Cycle and Radiologic-Pathologic Findings. — Shebel HM, Elsayes KM, Abou El Atta HM, Elguindy YM, El-Diasty TA. Radiographics : A Review Publication of the Radiological Society of North America, Inc. 2012.
8. Human Schistosomiasis. — Colley DG, Bustinduy AL, Secor WE, King CH. Lancet. 2014.
9. Consensus Definitions in Imported Human Schistosomiasis: A GeoSentinel and TropNet Delphi Study. — Tamarozzi F, Mazzi C, Antinori S, et al. The Lancet. Infectious Diseases. 2024.
10. FDA Drug Label. — Updated date: 2026-03-02. Food and Drug Administration.
11. Diagnostic Potential of S. mansoni Egg and Worm Antigens for Urogenital Schistosomiasis in Resource‐Limited Settings. — Sulaiman KA, Oriade TO, Auta T, et al. Parasite Immunology. 2025.
12. Intestinal parasites including Cryptosporidium , Cyclospora , Giardia , and Microsporidia , Entamoeba histolytica , Strongyloides , Schistosomiasis, and Echinococcus : Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. — La Hoz RM, Morris MI, AST Infectious Diseases Community of Practice. Clinical Transplantation. 2019.
13. Urinary Biomarkers and Haematuria as Indicators of Urogenital Schistosomiasis: A Systematic Review and Meta-Analysis. — Vere M, Ham-Baloyi WT, Oyedele O, Mduluza T, Melariri PE. Acta Tropica. 2025.
14. Performance of a Rapid Immuno-Chromatographic Test (Schistosoma ICT IgG-IgM) for Detecting Schistosoma-Specific Antibodies in Sera of Endemic and Non-Endemic Populations. — Hoermann J, Kuenzli E, Schaefer C, et al. PLoS Neglected Tropical Diseases. 2022.
15. Circulating Antigen Tests and Urine Reagent Strips for Diagnosis of Active Schistosomiasis in Endemic Areas. — Ochodo EA, Gopalakrishna G, Spek B, et al. The Cochrane Database of Systematic Reviews. 2015.
16. Sensitive Diagnosis and Post-Treatment Follow-Up of Schistosoma Mansoni Infections in Asymptomatic Eritrean Refugees by Circulating Anodic Antigen Detection and Polymerase Chain Reaction. — Hoekstra PT, Chernet A, de Dood CJ, et al. The American Journal of Tropical Medicine and Hygiene. 2022.
17. Real-Time PCR for Diagnosis of Imported Schistosomiasis. — Guegan H, Fillaux J, Charpentier E, et al. PLoS Neglected Tropical Diseases. 2019.
18. Radiological Findings in Imported Schistosomiasis at an International Health Unit in Barcelona, Spain. — Marqués-Sorinas M, Salvador F, Bocanegra C, et al. The American Journal of Tropical Medicine and Hygiene. 2025.
19. Significance of Echogenic Snow Sign as an Ultrasonography Finding for Diagnosis of Urogenital Schistosomiasis. — Kim MJ, Ryu K, Jin Y, et al. The American Journal of Tropical Medicine and Hygiene. 2016.
20. Point-of-Care Ultrasound Reveals Extensive Pathology in Gabonese Preschool-Age Children With Urogenital Schistosomiasis. — Remppis J, Verheyden A, Sultanli A, et al. PLoS Neglected Tropical Diseases. 2025.
21. The use of imaging to detect schistosomes and diagnose schistosomiasis. — Skelly PJ. Parasite Immunology. 2013.
22. Value of Ultrasonography in Investigating Morbidity Due to Schistosoma Haematobium Infection. — Degremont A, Burki A, Burnier E, et al. Lancet. 1985.
23. A 26-Year-Old Woman With Dysuria and Hematuria. — Duan M, Popat S, Coburn M, Woc-Colburn LE. Urology. 2021.
24. Macroscopic and Microscopic Imaging Modalities for Diagnosis and Monitoring of Urogenital Schistosomiasis. — Xie S, Shalaby-Rana E, Hester A, et al. Advances in Parasitology. 2021.
25. Detection of Cytological Abnormalities in Urothelial Cells From Individuals Previously Exposed or Currently Infected With Schistosoma Haematobium. — Smith-Togobo C, Mprah R, Yeboah EA, et al. PloS One. 2023.